Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune total assets
Total assets on the balance sheet at the end of each period.
Replimune's total assets was $373.94M at Sep 30, 2026. For fiscal 2026 it was $332.39M, down 39.7% from the year before. The highest annual figure on record is $646.59M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $332.39M | -39.7% |
| FY2025 | Mar 31, 2025 | $551.33M | +13.0% |
| FY2024 | Mar 31, 2024 | $487.72M | -24.6% |
| FY2023 | Mar 31, 2023 | $646.59M | +40.2% |
| FY2022 | Mar 31, 2022 | $461.19M | -15.1% |
| FY2021 | Mar 31, 2021 | $543.10M | +132.0% |
| FY2020 | Mar 31, 2020 | $234.10M | +51.7% |
| FY2019 | Mar 31, 2019 | $154.33M | +136.9% |
| FY2018 | Mar 31, 2018 | $65.15M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $373.94M | -4.0% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $252.45M | -46.2% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $332.39M | -39.7% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $333.59M | -44.7% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $389.45M | -21.8% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $469.51M | -12.2% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $551.33M | +13.0% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $603.63M | +13.3% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $498.20M | -11.4% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $534.97M | -11.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $487.72M | -24.6% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $532.93M | -21.5% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $562.40M | +29.0% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $603.89M | +31.4% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $646.59M | +40.2% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $678.55M | +39.8% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $436.10M | -13.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $459.43M | -12.3% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $461.19M | -15.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $485.28M | -13.2% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $503.46M | +60.2% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $523.72M | +58.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $543.10M | +132.0% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $559.20M | +123.3% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $314.24M | +107.5% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $329.58M | +129.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $234.10M | +51.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $250.42M | +64.5% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $151.44M | -1.5% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $143.54M | +142.1% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $154.33M | +136.9% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $152.19M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $153.82M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $59.29M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $65.15M | – |
See a number that looks wrong?